7ACC2: Carboxycoumarin MCT1 Inhibitor for Cancer Metabolism Research

Executive Summary: 7ACC2, available from APExBIO, is a highly potent carboxycoumarin derivative that inhibits both monocarboxylate transporter 1 (MCT1) and mitochondrial pyruvate transport with an IC50 of ~10 nM for lactate uptake in SiHa cells (product page). Its dual mechanism disrupts cancer cell metabolic homeostasis, resulting in delayed tumor growth and enhanced radiosensitivity in preclinical mouse xenograft models (Xiao et al., 2024). The compound is structurally and functionally suitable for advanced studies on lactate and pyruvate flux in cancer metabolism research. 7ACC2 is insoluble in water/ethanol but highly soluble in DMSO (≥47.5 mg/mL), and is intended for research use only.

Biological Rationale

Cancer cells reprogram their metabolism to support rapid proliferation and survival. The monocarboxylate transporter (MCT) family, specifically MCT1 and MCT4, enables cancer cells to efficiently shuttle lactate and pyruvate across plasma membranes (Xiao et al., 2024). MCT1 exhibits high affinity for L-lactate, facilitating uptake into oxidative tumor subpopulations. Lactate is both a metabolic intermediate and a signaling molecule that can modulate the tumor microenvironment and immune cell function. Inhibiting MCT1 disrupts lactate homeostasis, impairing tumor growth and progression. Moreover, mitochondrial pyruvate import is essential for oxidative phosphorylation and biosynthetic processes in cancer cells. Blocking these transporters presents a robust strategy to target cancer metabolism at multiple nodes (see related: metabolic dissection with 7ACC2).

Mechanism of Action of 7ACC2

7ACC2 is a synthetic carboxycoumarin (C18H15NO4, MW 309.32) that serves as a selective and potent inhibitor of MCT1, with an IC50 of approximately 10 nM for lactate uptake in human SiHa cervical carcinoma cells (APExBIO). It competitively blocks the transmembrane transport of short-chain monocarboxylates, notably lactate and pyruvate. In addition, 7ACC2 inhibits mitochondrial pyruvate transport, reducing pyruvate import into mitochondria and thus impeding oxidative metabolism. This dual blockade leads to accumulation of extracellular lactate and intracellular pyruvate, disrupting redox balance and energy production in tumor cells. The resulting metabolic stress can sensitize cancer cells to radiotherapy and limit their proliferative capacity (contrast: broad mechanistic insights).

Evidence & Benchmarks

• 7ACC2 inhibits lactate uptake in SiHa human cervical carcinoma cells with an IC50 of ~10 nM, demonstrating nanomolar potency (APExBIO).
• In SiHa mouse xenograft models, 7ACC2 administration significantly delayed tumor growth, especially when combined with radiotherapy (Xiao et al., 2024).
• 7ACC2 disrupts both plasma membrane MCT1-mediated lactate transport and mitochondrial pyruvate import, uniquely positioning it for studies on metabolic flux in cancer cells (internal review).
• The compound is insoluble in water and ethanol but is highly soluble in DMSO at concentrations equal to or greater than 47.5 mg/mL, supporting robust in vitro application (APExBIO).
• 7ACC2 does not inhibit all MCT isoforms; specificity is primarily for MCT1, with limited action on MCT2-4 under standard assay conditions (internal update).
• Dual inhibition of lactate and pyruvate flux by 7ACC2 has been shown to reprogram cancer cell metabolism and sensitize tumors to immune and radiotherapy interventions (Xiao et al., 2024).

Applications, Limits & Misconceptions

7ACC2 is widely applied in cancer metabolism research, particularly for:

• Dissecting the role of lactate shuttling in tumor microenvironment modulation.
• Studying metabolic symbiosis between oxidative and glycolytic cancer cell subpopulations.
• Evaluating radiosensitization and metabolic vulnerabilities in preclinical oncology models (see: immunometabolic integration).
• Investigating links between metabolic checkpoints (e.g., AMPK–STAT6 axis) and immune cell education in tumors (Xiao et al., 2024).

Common Pitfalls or Misconceptions

• Not a pan-MCT inhibitor: 7ACC2 shows strong selectivity for MCT1; it is not effective against all MCT isoforms.
• Not water/ethanol soluble: The compound must be dissolved in DMSO for experimental use; improper solvent selection can result in precipitation or assay failure.
• Not suitable for diagnostic or clinical use: 7ACC2 is strictly for laboratory research applications.
• Not a direct immune modulator: Its immunometabolic effects are indirect, mediated via metabolic reprogramming rather than direct immune cell targeting.
• Long-term solution storage is not recommended: 7ACC2 solutions are unstable over extended periods, even at -20°C.

Workflow Integration & Parameters

For optimal use, 7ACC2 (SKU: B4868) should be handled as follows:

• Solubilization: Dissolve in DMSO at ≥47.5 mg/mL. Do not attempt to dissolve in water or ethanol (product details).
• Storage: Store powder at -20°C. Prepare fresh solutions for each experiment; avoid long-term storage of solutions.
• Shipping: Shipped on blue ice to maintain stability during transit.
• Concentration: Use nanomolar to low micromolar concentrations for cell-based assays; titrate as required by cell line sensitivity and experimental design.
• Controls: Include DMSO-only controls to account for solvent effects.

To deepen understanding, see this strategic roadmap for immunometabolic integration—it extends the mechanistic focus here by mapping 7ACC2's use to AMPK–STAT6 axis targeting in tumor-associated macrophages.

Conclusion & Outlook

7ACC2, provided by APExBIO, is a validated, dual-action carboxycoumarin inhibitor essential for advanced cancer metabolism and immunometabolic research. Its nanomolar efficacy, selectivity for MCT1, and mitochondrial pyruvate transport inhibition enable precise dissection of lactate and pyruvate flux in tumor models. Robust preclinical evidence supports its use for investigating metabolic vulnerabilities and radiosensitization. Users should adhere to best-practice handling and storage guidelines and recognize its limitations with respect to target specificity and research-only designation. For applications requiring rigorous control of lactate and pyruvate dynamics in the tumor microenvironment, 7ACC2 represents a premier choice.